https://www.nytimes.com/2026/09/07/science/ai-generated-drug-longevity.html
Posts Tagged ‘insilico’
Early Data Indicates an A.I.-Generated Drug Could Slow Aging – The New York Times
September 28, 2026Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment | Nature Biotechnology
September 28, 2026Can an AI-designed drug slow aging?
September 28, 2026https://ctrk.klclick.com/l/01M2ZDVD112D4GPK2S1Z8EH3BR_23
QT:{{”
Elysium Abstract
…
An AI-designed drug sent six aging clocks backward
In a 12-week phase 2a trial, an AI-designed drug for idiopathic pulmonary fibrosis reduced predicted biological age across six protein-based aging clocks in 42 participants. The findings don’t prove the drug slows aging, but they point to a new way to study it. “This is one of the few concrete examples of a drug largely designed with generative AI,” says Mark Gerstein, Ph.D., Albert L. Williams Professor of Biomedical Informatics at Yale and a member of Elysium’s Scientific Advisory Board. “Moreover, it’s impressive to see how AI was used throughout the whole drug-development process, from upstream target finding to analyzing the downstream trial for results related to longevity.” He adds: “This last use has great promise for aging research, showing how conventional disease trials can be made into dual-purpose designs suitable for studying longevity.” (Nature Biotechnology)
“}}
Chemistry42: An AI-Driven Platform for Molecular Design and Optimization
September 27, 2026Chemistry42: An AI-Driven Platform for Molecular Design and
Optimization – PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC9930109/
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models – PMC
September 26, 2026https://pmc.ncbi.nlm.nih.gov/articles/PMC11738990/
QT:{{”
Using AI-driven methodology, we generated INS018_055, a small-molecule TNIK inhibitor, which exhibits desirable drug-like properties and anti-fibrotic activity across different organs in vivo through oral, inhaled or topical administration…. Its safety and tolerability as well as pharmacokinetics were validated in a randomized,
double-blinded, placebo-controlled phase I clinical trial
(NCT05154240) involving 78 healthy participants.
“}}
Ren, F., Aliper, A., Chen, J., Zhao, H., Rao, S., Kuppe, C., Ozerov, I. V., Zhang, M., Witte, K., Kruse, C., Aladinskiy, V., Ivanenkov, Y., Polykovskiy, D., Fu, Y., Babin, E., Qiao, J., Liang, X., Mou, Z., Wang, H., . . . Zhavoronkov, A. (2024). A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology, 43(1), 63–75.
https://doi.org/10.1038/s41587-024-02143-0
